INTRODUCTION
This article summarizes pharmacokinetic parameters of 20 different drugs. The parameters were estimated by uniform methods for an ncompartment open mammillary model in which elimination was assumed to occur only from the central compartment. For various reasons, some of the reported parameters differ appreciably from those reported in the original articles. Some uses of the parameters are discussed.
This was a special project undertaken by members of the Pharm. 560 (Pharmacokinetics) class in the College of Pharmacy, The University of Michigan, during the Winter Semester, 1976. The names of the class members are listed in the Acknowledgments section. This availability underlines the fact that no part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission of the publisher. Shipment is prompt; rate per article is $7.50.
EXPERIMENTAL

Raw Data
The raw data were either obtained from the original articles or obtained after request from the senior author. The drugs and references are as follows: ampicillin (1), diazepam (2) , diphenhydramine (3), nortriptyline (4), phenytoin (5) , tranexamic acid (6) , warfarin (7) , acetylsalicylic acid and salicylic acid (8) , cefazolin (9) , clindamycin phosphate and tobramycin (10, 11) , digoxin (12) (13) (14) (15) (16) , griseofulvin (17) , pentobarbital (18) , pindolol (19) , quercetin (20) , spectinomycin (21) , sulfisoxazole (22) , and cephalexin (23) .
Methods
For acetylsalicylic acid (8) , diazepam (2) , digoxin (12) , griseofulvin (17) , and salicylic acid (8) , the coefficients and exponents of the polyexponential equations which the original authors had fitted to the data were employed.
In all other cases, the procedure was as follows. Each set of plasma (or serum) concentration-time data observed either following bolus intravenous injection or subsequent to the termination of a constant-rate intravenous infusion was evaluated by the program CSTRIP (24) and a digital computer. The operator requested the program to print out the optimum polyexponential equation for one, two, three, and four exponential-terms. The "optimum," decided by the program, is the equation which arises from the grouping of the points for each exponential term which yields the minimum sum of squared deviations. For each data set, the operator then decided the appropriate number of exponential terms for a nonlinear least-squares fit. The latter was usually decided by the regression analysis of C vs. C and use the percentage improvement in r22, the coefficient of determination, which is printed out by the program; criteria used in the decision are shown in Table I .
In practice, in most cases the decision was made quite easily, since, for example, if the optimum number of terms was two, the r 2 value for the two-term equation was higher than for a three-term or four-term equation. Sometimes an asymptotic r22 value was reached at the two-term level such that the r 2 values for the two-term, three-term, and four-term polyexponential equations were the same. Each set of data was then fitted to the appropriate polyexponential equation using the program NONLIN (25) and a high-speed digital computer; the preliminary estimates of the coefficients and exponents used as input for NONLIN were those obtained from the program CSTRIP. If there was any doubt about the required number of 
where rn is the number of plasma concentration measurements.
exponential terms needed, then NONLIN least-squares fits with both n and n + 1 terms were obtained and the F test described by Boxenbaum et al. (26) was used. In each fitting, the squared deviations were weighted according to the reciprocals of the observed concentrations. All fittings were performed to the general polyexponential equation 1 for bolus intravenous data and to equation 2 for post-constant-rate infusion data.
Cp= ~ C~e -A''
In equations 1 and 2, Cp symbolizes the plasma (or serum) concentration at time t, C~ is the coefficient of the ith exponential term for bolus intravenous data, Y~ is the coefficient of the ith exponential term for post constant-rate intravenous infusion data, and,~i is the exponent of the ith exponential term. If only one infusion had been administered over T hours, then the equation of the form of equation 2, obtained from postinfusion data, was converted to the corresponding equation 1 (simulating the situation if the total infused dose had been given as a bolus intravenous injection) by use of +A.T C~ = hiTY~/(e ' -1)
Such a correction of the coefficients should be made even though only very short infusions have been administered. Several authors (6, 18, 20) failed to adjust the coefficients by means of equation 3 (or did not fit data to an equation which was appropriate for an infusion), and hence all their reported pharmacokinetic parameters were subject to error.
In the case of nortriptyline (4), multiple infusions were administered. Five infusions, each containing 11.4 mg of nortriptyline hydrochloride in 25 ml of saline, were given over 10-rfiin periods with intervals of 5 min between infusions. In this case, Cp is given by
where Zi represents everything within the square brackets and the coefficient is obtained by fitting postinfusion data. Equation 5 was then used to convert the Z/values to C~ values:
where {P~} represents everything in the same type of braces in equation 4. In equation 4, q = 10 min (0.166 hr) and is the duration of each infusion; p = 5 min (0.083 hr) and is the interval between infusions, p +q = 0.25 hr; m'= 4
and is the number of p+q periods; t* = 1.166 hr= (0-1) (p+q)+q; 0 = 5 and is the number of infusion periods; and t is the time from the start of the first infusion. The pharmacokinetic parameters were calculated using equations 6-11, reported by Wagner (27) .
tl/2 = 0.693/A 1 (11) In equations 6-11, D is the intravenous dose; C1 and h I are the coefficient and exponent, respectively, such that h 1 is the smallest of the hg's of the polyexponential equation; Vp is the volume of the plasma (reference) compartment, Vass is the volume of distribution steady state; Vearea is that volume which, when multiplied by Cp in the log-linear phase (when only C1 e -~lt is making a significant contribution to Cv), is equal to the amount of drug in the body, and also such that Clp = Vd .... " hi; Vaext is the extrapolated volume of distribution; fl n is the plasma (or serum) clearance; and tl/2 is the apparent elimination half-life.
In order to avoid arithmetic errors, equations 6-11 were programmed on an electronic calculator. Input was the dose and the coefficients and exponents; output was the left-hand sides of equations 6-11 in numerical form. In addition, the students calculated the parameters separately, providing an additional check on accuracy.
RESULTS
The numbers of exponential terms used in the NONLIN fittings are summarized in Table II . In all cases reported, the NONLIN fits of individual data sets were excellent as judged by the r 2 values obtained:
These usually exceeded 0.995. Several of the data sets of clindamycin phosphate in subjects under dialysis and in uremic subjects and of pentobarbital fell in the region 0.988 < r 2 < 0.995.
The data of subject 3, given cefazolin (9), were excluded, since the fit was not good (r~ = 0.861, Corr = 0.982), particularly at the tail end of the curve. Table III lists doses and pharmacokinetic parameters for eight drugs where data came from articles which listed the body weights of the individual subjects or patients. For these eight drugs, the volumes are given in liters/kg and the clearance in liters/(kg• hr); this is a distinct advantage since such parameters usually have smaller coefficients of variation than corresponding values expressed in liters and liters/hr, respectively.
Tables IV and V list doses and pharmacokinetic parameters of 12 drugs where the data came from articles which did not list the body weights of individual subjects. Hence for these drugs volumes are given in liters and clearances in liters/hr. Tables III-V also list the number of subjects or patients for which data were evaluated, the type of subjects or paffents, and the mean, range, and coefficient of variation of each estimated parameter.
The data given in Table IV for digoxin were calculated using the coefficients and exponents of biexponential equations reported by Koup et al. (12) ; these were obtained by the simultaneous fitting of both serum concentration and urinary excretion data. The individual subject values calculated in this study are listed in Table VI , along with variance ratios (F values) and results of paired t tests comparing bolus intravenous and infusion methods. It should be noted that paired t tests are valid even when the variances are not homogeneous (i.e., the F value is significant at p -< 0.05). Table VII lists the digoxin pharmacokinetic parameters obtained from postinfusion data of Wagner et al. (16) . Table VIII lists (for the first time) the apparent elimination half-lives of digoxin estimated from terminal oral data following digoxin tablets (Burroughs & Wellcome) in the study of Wagner et al. (16) .
DISCUSSION
There is no doubt that the method of data analysis used in this article results in improved parameter estimates. However, they are still potentially subject to computer-and methodological-derived error. The NONLIN is 
.
bValue is considerably different than that calculated from the same data by Koup et al. (12) . one of the better programs for nonlinear analysis, but is still subject to false minima. Fell and Stevens (28) showed that the NONLIN program resulted in relatively poor estimates of the parameters from data derived for one-and two-body-compartmental models. The use of r 2 for selection of the number of exponential terms and as a criterion of fit is subject to error since it is a measure of overall fit to the model.
Variability of Parameters
Of the volumes V~ss, Vd ..... and Vaext, there is a general tendency for the coefficients of variation (C.V.) to increase in the order given, as well as the magnitudes of the volumes. That is, in general, Vdss not only is the smallest of these three volumes but also has the smallest C.V. This is fortunate since Vd~s is probably the most useful volume pharmacokinetically. The C.V. of Vd~ is less than the C.V. of Vd .... for ampicillin, phenytoin, digoxin, griseofulvin, cephalexin, spectinomycin, and sulfisoxazole. The C.V. of Vd~ is approximately equal to the C.V. of Va .... for diazepam, nortriptyline, warfarin, tobramycin, ASA, clindamycin phosphate, pentobarbital, quercetin, and salicylic acid.
The C.V. of CIp is greater than the C.V. of Vds~ for phenytoin, warfarin, digoxin, griseofulvin, pentobarbital, and quercetin. The C.V. of Clp is approximately equal to the C.V. of Vds~ for ampicillin, diazepam, nortriptyline, tobramycin, and clindamycin phosphate. The C.V. of Va~ is greater than the C.V. of Clp for ASA, cefazolin, pindolol, salicylic acid, spectinomycin, and sulfisoxazole (see Tables III-V) .
As pointed out earlier by Koup et al. (12) , the C.V. of each pharmacokinetic parameter when digoxin was given by intravenous infusion is less than the corresponding C.V. when the drug was given by bolus intravenous injection (see Table VI ). The variance ratios for bolus/infusion are significant (p --< 0.05) for 6-day urinary excretion, Valse, and Vdarea, but are not significant (p >0.05) for Vp, Clp, tile, and AUC.
The variabilities of the pharmacokinetic parameters for tobramycin (Table III) and clindamycin phosphate (Table IV) in chronic renal patients undergoing dialysis are quite large, indicating considerable patient-topatient variability.
Vd exi
The extrapolated volume of distribution, Vaext, is probably the most common "volume of distribution" reported in the medical literature, yet it is the most inappropriate volume from a pharmacokinetic standpoint. Many assume that Clp = Wdext 9 hl, but this has no foundation in pharmacokinetic theory. If the model is the simple one-compartment open model, then Vaext = Vdarea = Vdss and the clearance is equal to Vdext" hi. However, in all other cases Clp = Vdare~ " ~ 1" Hence, in most cases, the only time that Vdext is useful in a pharmacokinetic sense is when Vdext is only slightly larger than Wdare a and can be used as an estimate of Vaar~a. Of the 20 drugs studied, this approximation holds for only seven drugs (35%), namely for nortriptyline, tranexamic acid, warfarin, tobramycin, griseofulvin, pentobarbital, and salicylic acid (see Tables III-V) . For the other 13 drugs, Vd~xt is of little use pharmacokinetically, except as noted below (see equation 17) .
Use of Equations 3-5
Readers' attention is drawn to the importance of applying equations 3-5 to infusion data, even though constant-rate infusions are given over only a few minutes. A bolus injection in the pharmacokinetic sense means injection of the entire dose all at once at zero time, and the bolus intravenous equations have been derived with that assumption. In applying equation 3, the biggest difference in the Y~ 's and corresponding C~'s will occur with I12 and C2 for a biexponential equation and in Y2 and C2 and Y3 and C3 for a triexponential equation. Also, if the investigator wishes to give a short infusion for safety purposes, the infusion should be administered at a constant rate and the infusion time accurately determined for each subject, so that equation 3 may be applied correctly.
Reporting Body Weights
It is a distinct advantage to report the body weights of individual subjects or patients in pharmacokinetic papers. The C.V.'s of the various pharmacokinetic parameters are almost always lower when corrections have been made for body weight than when they have not. This was tested with the drugs given in Table III and found to be true, and that is why the volumes are expressed in units of liters/kg and the clearances in liters/(kg x hr). Thus, if one is going to make estimates for a particular subject or patient from the tabled numbers, the body weight corrected value multiplied by the particular patient's body weight will provide a better estimate of a mean value and the possible range of the value. It is suggested that journal editors accept pharmacokinetic articles only when individual body weights have been listed. The senior author of this article also believes that all raw data should be included in an article, particularly when they are intravenous data. Showing data in graphical form does not allow future reevaluation of data, such as is done in this article. It is really the raw data which have archival value, not someone's interpretation of the data. Theory and methods change with time, and reevaluation of data is often necessary at some later date. In the present instance, the senior author believed such a comparison of pharmacokinetic parameters should be done only when all data were evaluated by uniform methods.
Number of Exponential Terms
The type of data evaluated (i.e., either bolus intravenous or postinfusion) and the number of exponential terms used in the fittings are summarized in Table II. The table also indicates whose exponents and coefficients were used in applying equations 6-11.
It should be noted that the same number of exponential terms are not always required to fit each member's data in a given panel administered a given drug. In the case of tobramycin, clindamycin phosphate, and pindolol, two data sets for each drug required only one exponential term, while the remainder required two exponential terms. We evaluated the phenytoin data of Gugler et al. (5) with triexponential equations, whereas the original authors used biexponential equations. Although the data evaluated for both phenytoin and salicylic acid fit the linear model at the low doses employed, it should be realized that these drugs obey Michaelis-Menten kinetics at higher doses.
Digoxin
Koup et al. (12) stated: "Urinary excretion data are essential for proper pharmacokinetic analysis of digoxin disposition and reveal a slower elimination rate than that suggested by earlier studies which determined only serum concentrations." This statement is true for the earlier study of Kramer et al. (13) , but not for the earlier study of Wagner etal. (16) . The reason lies in the assay method published by Stoll et al. (29) , which showed that lower plasma and serum levels of digoxin can be measured than those reported by either Kramer et al. (13) or Koup et al. (12) . The pharmacokinetic parameters, particularly C1 m tl/2, and AUC, estimated from the plasma digoxin concentrations after bolus intravenous administration in the study of Wagner et al. (16) , shown in Table VII , are very similar to those obtained from the data of Koup et al. (12) , shown in Table VI . Also, the apparent elimination half-lives of digoxin, not formerly reported but now shown in Table VIII , which were estimated from plasma digoxin concentrations measured by radioimmunoassay (29) following oral dosing with digoxin (Burroughs & Welcome tablet) are essentially the same as those reported by Koup et al. (12) . As indicated by the table heading of Table VIII, the log-linear phase of digoxin elimination does not commence until about 24 hr, when the digoxin concentration is about 0.3 ng/ml, requiring a more sensitive assay than the routine radioimmunoassay and sampling each day in the 24-96 hr range after a single dose. In the studies of Kramer et al. (13) , digoxin concentrations were measured down only to about 0.5 ng/ml, and in the studies of Koup et al. (12) concentrations in serum were measured down only to about 0.3 ng/ml.
Greenblatt et al. (14) recommended use of digoxin given by slow infusion over a 1-hr period and 6-day urinary excretion of apparent digoxin as bioavailability standard. Table VI, derived from the data of Koup et al. (12) , indicates that mean 6-day urinary excretion of apparent digoxin was 566 ~g for bolus and 610 #g for infusion; the 8% difference is significant (0.05 >p > 0.02) by paired t test. However, in both cases the C.V.'s are very small, being 7.8% for bolus and 3.4% for infusion. It should also be noted that the total AUC (obtained by integrating the polyexponential equations between the limits of 0 and ~) averages 71.1 for bolus and 57.5 for infusion--a 24% difference, which did not test significant (0.10 > p > 0.05).
Stoll and Wagner (15) pointed out that the bolus-infusion difference in 6-day urinary excretion could be caused by the nonspecific radioimmunoassay used (26) and the higher ratio of metabolites/digoxin in urine than in plasma.
USE OF THE PHARMACOKINETIC PARAMETERS Baseline Data for Disease State Studies
Most of the tabled values were calculated from data obtained when normal volunteers were given the drugs intravenously. Hence they may serve as baseline data for comparison purposes with similar values estimated from data obtained after administration of the same drugs intravenously to patients with various specific diseases.
Constant-Rate Intravenous Infusion Therapy
The mean values of the parameters may be most useful for initiating therapy with one of the drugs in a given patient. Some examples are given below, but these are not intended to be exhaustive or complete.
1. A safe method for rapidly achieving a desired steady-state plasma concentration, C'p ', for drugs whose plasma concentration is describable by a biexponential equation was given by Wagner (30) . The solution is such that the steady state is achieved as rapidly as possible after a final infusion rate is commenced. The method involves administration of two consecutive constant-rate infusions--one at a rate Q1 over T hours, and the second at a rate Qz starting at T hours and maintained as long as steady state is desired. The needed infusion rates are calculated with equations 12 and 13, using the nomenclature of this article. Suggestions for choosing the time Twere given in the original article (30) . The method was later generalized by Vaughan and Tucker (31) .
Oi = O2/(1-e ~,T)
The mean values of the exponents, ht, h2, and k3, obtained in the fittings reported in this article are shown in Table IX . Table IX___under ampicillin we obtain A1 = 0.616 hr -~ and from Table III However, it is not usually safe to give the loading dose all at once at zero time, then start the infusion at the same time. Let us assume we wish to give a loading dose over 0.5 hr. Then we must calculate how much of the bolus DE is lost in 0.5 hr, then add this amount to the bolus DE to get the correct loading dose to administer as an infusion over 0.5 hr.
One can "synthesize" the typical bolus intravenous equation using equation 17, reported by Wagner (30) :
The By the method of Wagner (27) , the Q1 rate obtained was 11.1 mg/kg/hr for T=0.5hr. Thus in 0.5hr the dose delivered was 5.55 mg/kg, which is essentially the same as the total DL of 5.51 mg/kg calculated above. Hence the method of Wagner (27) 
Clp Thus one could make various estimates of A ~ for different infusion rates Q, using tabled mean values of Va~ and Clp.
Intermittent Bolus Intravenous Therapy
Approximations for clinical use may be made with equation 17. Example 2: Suppose we use the mean tabled val____ues for digoxin (Tables  IV and IX (27) Now, integration of equation 27 between the limits of 0 and 0o gives an AUC of 56.9 (ng/ml) • hr. The mean AUC based on 16 data sets (Table VI) was 64.3, hence agreement is reasonable.
Suppose one wished to predict the steady-state level, ~s, and the minimum steady-state level, C~p in, if 0.5 mg of digoxin was given as a bolus intravenous dose once a day (~" = 24 hr). The steady-state concentration at any time t after a dose of 0.5 mg at steady state will be estimated by equation 28, in which the coefficients have been corrected for dose. x (1 -e -('99) (24))]/24 = 1.58 ng/ml (30) The discrepancy in the "answers" given by equations 29 and 30 does not reside in the equations, but rather in the fact that the "answer" was obtained using mean values of Vp and Vaext, while the other "answer" was obtained using the mean value of Ctp. For clinical purposes, the discrepancy is not important.
The 
Estimation of CIj, for a Particular Patient
Suppose the tabled Va .... (mean value) has a reasonably small coefficient of variation (C.V.) and one has some method of estimating A1 with endogenous creatininr clearance, such as given by Wagner (33) , or from a correlation of h/z with serum creatine concentration, then obtaining )t, with equation 11. Then one can estimate the clearance for a particular patient from In equation 34, Dm/'r is the "dose rate," where Dm is the maintenance dose and z is the uniform dosing interval; FF* is the "bioavailability factor," where F is the fraction of the dose in the dosage form which is absorbed and F* is the fraction of that drug absorbed which reaches the general circulation as a result of the "first-pass" effect. Hence, to use the Clp values listed in this article to make predictions for oral therapy, one must know the value of FF* for the particular drug and the particular dosage form of the drug which is used. For example, Jusko and Lewis (1) reported that for ampicillin oral capsules, sold by Bristol Laboratories, FF* averaged 0.32, with a range of 0.21-0.46. Work in several laboratories has indicated that the mean value of FF* for digoxin tablets, manufactured by Burroughs & Wellcome, is 0.6. For warfarin, given in 5-mg tablets, sold by Endo Laboratories, the value of FF* is essentially unity (i.e., all the drug is absorbed and there is essentially no "first-pass" effect).
If the Clp values tabled in this report are used, and an estimate of FF* is known, then an estimate of the "dose rate" needed to attain a desired average steady-state plasma level, C;, may be made with equation 34. Once the ratio, Dm/z is obtained, then a reasonable value of ~" (i.e., 4, 6, 8, 12, or 24 hr) and a reasonable value of Dm (i.e., something available from a commercial product, such as one tablet, one-half tablet, etc.) are chosen, so that one obtains the required "dose rate." Obviously, the smaller the value of -r, the less fluctuation there will be in the steady-state levels, i.e., the smaller the difference between C-~ ~' and C~ in. 
